WO2009034431A3 - Controlled-release dosage forms for varenicline - Google Patents

Controlled-release dosage forms for varenicline Download PDF

Info

Publication number
WO2009034431A3
WO2009034431A3 PCT/IB2008/002311 IB2008002311W WO2009034431A3 WO 2009034431 A3 WO2009034431 A3 WO 2009034431A3 IB 2008002311 W IB2008002311 W IB 2008002311W WO 2009034431 A3 WO2009034431 A3 WO 2009034431A3
Authority
WO
WIPO (PCT)
Prior art keywords
varenicline
controlled
dosage forms
release dosage
antioxidant
Prior art date
Application number
PCT/IB2008/002311
Other languages
French (fr)
Other versions
WO2009034431A2 (en
Inventor
Barbara Alic Johnson
Kenneth Craig Waterman
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of WO2009034431A2 publication Critical patent/WO2009034431A2/en
Publication of WO2009034431A3 publication Critical patent/WO2009034431A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)

Abstract

A controlled release pharmaceutical composition of varenicline or a pharmaceutically acceptable salt thereof wherein said controlled release pharmaceutical composition comprises a coating and an antioxidant wherein said antioxidant is present in an amount equal to a weight percent greater than about 0.1 % but less than 5% of the coating layer.
PCT/IB2008/002311 2007-09-10 2008-08-29 Controlled-release dosage forms for varenicline WO2009034431A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97101707P 2007-09-10 2007-09-10
US60/971,017 2007-09-10

Publications (2)

Publication Number Publication Date
WO2009034431A2 WO2009034431A2 (en) 2009-03-19
WO2009034431A3 true WO2009034431A3 (en) 2009-11-19

Family

ID=40032575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/002311 WO2009034431A2 (en) 2007-09-10 2008-08-29 Controlled-release dosage forms for varenicline

Country Status (1)

Country Link
WO (1) WO2009034431A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200276113A1 (en) * 2016-01-08 2020-09-03 Ctc Bio, Inc. Taste-masked and orally administered pharmaceutical preparation containing varenicline or pharmaceutically acceptable salt thereof
KR20180058644A (en) * 2016-11-24 2018-06-01 에스케이케미칼 주식회사 Sustained release pharmaceutical formulation of varenicline and preparation method thereof
GB2561333B (en) 2017-02-17 2020-06-03 Bo Soederpalm Treatment of alcohol use disorder
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
KR102235848B1 (en) * 2019-11-20 2021-04-05 충북대학교 산학협력단 Tablet for delayed release of varenicline or pharmaceutically acceptable salts thereof
WO2022271600A1 (en) * 2021-06-25 2022-12-29 Handa Pharma, Inc. Stable varenicline dosage forms
EP4169516A1 (en) * 2021-11-05 2023-04-26 Alfred E. Tiefenbacher (GmbH & Co. KG) Prevention of the conversion of pharmaceutical agents into toxic n-nitrosamine compounds
WO2023012376A2 (en) * 2021-11-05 2023-02-09 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Prevention of the conversion of pharmaceutical agents into toxic n-nitrosamine compounds
KR20230068877A (en) * 2021-11-11 2023-05-18 주식회사 아울바이오 Microspheres containing high-dose varenicline, method for preparing the same, and pharmaceutical composition comprising the same
CN114088843B (en) * 2021-11-26 2024-01-30 上海皓鸿生物医药科技有限公司 Detection method for nitrosamine genotoxic impurities in valance intermediate
WO2023275413A2 (en) * 2021-12-23 2023-01-05 Medichem, S.A. Solid pharmaceutical formulations of varenicline

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235850A1 (en) * 2003-05-20 2004-11-25 Pfizer Inc Pharmaceutical compositions of varenicline

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4093105A (en) 1977-10-19 1978-06-06 N. T. Gates Company Plastic container with vent means
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US6133361A (en) 1996-02-03 2000-10-17 Mitsubishi Gas Chemical Company, Inc. Oxygen-absorbing composition, oxygen-absorbing resin composition, packing material, multi-layered packing, oxygen absorber packet, packing method and preservation method
BR9810403A (en) 1997-07-01 2000-08-29 Pfizer Sertraline salts and sustained release dosage forms of sertraline
IL136727A0 (en) 1997-12-31 2001-06-14 Pfizer Prod Inc Aryl fused azapolycyclic compounds
US6605610B1 (en) 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
AU2001276608A1 (en) 2000-08-30 2002-03-13 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
EP1243524A3 (en) 2001-03-16 2004-04-07 Pfizer Products Inc. Pharmaceutical kit for oxygen-sensitive drugs
JP2005528330A (en) 2001-11-30 2005-09-22 ファイザー・プロダクツ・インク Pharmaceutical composition of 5,7,14-triazatetracyclo [10.3.1.02, 11.04,9] -hexadeca-2 (11) 3,5,7,9-pentaene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040235850A1 (en) * 2003-05-20 2004-11-25 Pfizer Inc Pharmaceutical compositions of varenicline

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KENNETH C WATERMAN ET AL: "N-methylation and N-formylation of a secondary amine drug (varenicline) in an osmotic tablet", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 97, no. 4, 1 April 2008 (2008-04-01), pages 1499 - 1507, XP008111696, ISSN: 0022-3549 *
PUZ MICHAEL J ET AL: "Use of the antioxidant BHT in asymmetric membrane tablet coatings to stabilize the core to the acid catalyzed peroxide oxidation of a thioether drug.", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY 2005, vol. 10, no. 1, 2005, pages 115 - 125, XP002546552, ISSN: 1083-7450 *
WATERMAN ET AL.: "N-methylation and N-formylation of a secondary amine drug (varenicline) in an osmotic tablet", J PHARM SCI, vol. 97, no. 4, 21 August 2007 (2007-08-21), pages 1499 - 1507, XP002546561, Retrieved from the Internet <URL:http://www3.interscience.wiley.com/journal/115805949/abstract?CRETRY=1&SRETRY=0> [retrieved on 20090909] *

Also Published As

Publication number Publication date
WO2009034431A2 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2009034431A3 (en) Controlled-release dosage forms for varenicline
WO2009113703A3 (en) Orally-disintegrating solid preparation
WO2011084593A3 (en) Abuse-resistant formulations
WO2011106416A3 (en) Abuse-resistant formulations
WO2009008006A3 (en) Pharmaceutical compositions for gastrointestinal drug delivery
NZ600123A (en) Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
WO2011039768A3 (en) Pharmaceutical compositions for reducing alcohol-induced dose dumping
WO2009092129A8 (en) Delayed release pharmaceutical composition of duloxetine
NZ589469A (en) Niacin and NSAID combination for reducing niacin-induced flushing
HRP20210618T1 (en) Increasing drug bioavailability in naltrexone therapy
NZ589017A (en) Solid pharmaceutical formulation with delayed release
WO2008113901A3 (en) Composition with controlled release of levetiracetam and method for preparing same
JP2013508289A5 (en)
WO2006096194A8 (en) Drinkable immediate release tablet made with direct compression of memantine or neramexane
WO2009057138A3 (en) Controlled release pharmaceutical compositions of tolterodine
WO2008008592A3 (en) Multi-particulate formulation having tramadol in immediate and controlled release form
WO2008062475A3 (en) Pharmaceutical compositions of ursodiol
WO2007145863A3 (en) Sustained release formulation of naltrexone
WO2008056375A3 (en) Pharmaceutical formulations comprising valsartan
MX2011007779A (en) Galenic formulations of organic compounds.
WO2011141791A3 (en) Extended release formulations of desvenlafaxine base
WO2009052353A3 (en) Trospium pharmaceutical formulations
WO2008077813A3 (en) Orally disintegrating tablets
WO2007146068A3 (en) Controlled release alfuzosin hydrochloride formulation
WO2012014052A3 (en) Novel coated extended release pharmaceutical compositions containing paliperidone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08807003

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08807003

Country of ref document: EP

Kind code of ref document: A2